ClinicalTrials.gg
Not yet recruitingNCT06974942Updated May 16, 2025

Physical Activity in Adolescents With Familial Mediterranean Fever

An observational study in Familial Mediterranean Fever (FMF ), sponsored by Istanbul University - Cerrahpasa. Not yet recruiting at 1 site in Turkey. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Istanbul University - Cerrahpasa · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
172
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 20 studies in Familial Mediterranean Fever with a site in Turkey — 7 open to participants now, 8 under way, none of them phase 3. Familial Mediterranean Fever · Turkey.

Planned enrollment
2nd of 10
172 · median 80
Started
2025
with 5 others
Observational
10 of 20
4 open now
Registered
17th of 20
by date
Lead sponsor
5 of 20
Istanbul University - Cerrahpasa

Among the 20 studies in Familial Mediterranean Fever with a site in Turkey, this one is the 2nd largest by planned enrollment of the 10 observational ones, is one of 6 that started in 2025, is one of 10 observational ones, and was the 17th registered.

By phase

20 studies; the count open now beside each. This study's row is marked.

Observationalthis study10 · 4 open
No phase4 · 2 open
Phase 23 · 1 open
Phase 11 · 0 open
Phase 2/31 · 0 open
Phase 41 · 0 open

By the year they started

First in 2001; this study’s year is marked. 6 started in 2025.

Size and results

Median enrollment 60 across the 10 interventional studies, 80 across the 10 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 20 studies in Familial Mediterranean Fever with a site in Turkey, or all of them as a file.
02

Study summary

Familial Mediterranean Fever (FMF) is one of the most common autoinflammatory rheumatic diseases in childhood. Problems such as joint pain, muscle weakness, decreased aerobic capacity, and fatigue seen in children and adolescents with rheumatic disease may lead to low physical fitness levels. Limitation of physical performance is one of the possible consequences of chronic diseases that occur during childhood. At the same time, children with chronic illness face many challenges in participating in physical activity. Pediatric patients with rheumatic diseases tend to be physically inactive and, compared to their healthy peers, generally avoid participating in physical activity due to the limitations imposed by the disease. Often, the disease itself paves the way for decreased functional capacity and the development of deconditioning. Therefore, prescribing physical activity and exercise to pediatric populations with chronic illnesses is of great importance. This approach helps alleviate both the symptoms related to chronic diseases and the lifelong complications secondary to pharmacological treatments, and also prevents the development of new chronic conditions.

Participation in adequate physical activity is one of the most important behaviors individuals can adopt to maintain their health and well-being. Globally, public health physical activity guidelines address the exercise needs of children and adolescents. The European Alliance of Associations for Rheumatology (EULAR) highlights in its physical activity and exercise guidelines for patients with rheumatic diseases that the physical activity recommendations made for the general population are also applicable to patients with rheumatic diseases.

With this cohort study, it is aimed to examine physical activity (PA) in detail in adolescents diagnosed with FMF and to compare them with healthy peers. This study is one of the first in our country to provide comprehensive data on the PA levels of adolescents with FMF. The findings obtained will contribute to understanding PA levels and exercise perception, and guide the planning of exercise programs to be developed for these individuals. Moreover, the results of the study may also serve as a basis for future research in children and adolescents with various chronic diseases, especially those with FMF.

03

Conditions studied

  • Familial Mediterranean Fever (FMF )

Keywords

  • Familial Mediterranean Fever
  • Physical Activity
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Our study consists of two cohorts, where the physical activity level, physical activity competence, and motivation for physical activity of adolescents with Familial Mediterranean Fever (FMF) will be evaluated and compared with their healthy peers.

Eligibility criteria

Inclusion criteria for patients with FMF:

  • Be between 12-18 years of age
  • Have been diagnosed with FMF for at least 6 months at the Pediatric Rheumatology Department of Istanbul Faculty of Medicine
  • Be undergoing routine medical treatment for FMF
  • Be willing to participate in the study

Exclusion criteria for patients with FMF:

  • Adolescents whose participation in the study is not wanted by their family
  • Having vestibular or neurological balance problems
  • Presence of scoliosis, leg length discrepancy, or recent lower extremity surgery
  • Adolescents with visual or hearing impairments

Inclusion criteria for healthy peers:

  • Be between 12-18 years of age
  • Be willing to participate in the study

Exclusion criteria for healthy peers:

  • Adolescents whose participation in the study is not wanted by their family
  • Having vestibular or neurological balance problems
  • Presence of scoliosis, leg length discrepancy, or recent lower extremity surgery
  • Adolescents with visual or hearing impairments

Exclusion criteria for removal:

  • Leaving at least 3 questions unanswered in the questionnaires
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
172 participants (estimated)
Patient registry
No

Groups and cohorts

  • Familial Mediterranean Fever

    The study will include 76 patients diagnosed with Familial Mediterranean Fever who are being followed at the Division of Pediatric Rheumatology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University.

  • Healthy control

    The study will include healthy peers of adolescents diagnosed with FMF.

06

What researchers measure

Primary outcomes

  1. Adolescent Physical Activity Questionnaire (PAQ-A)

    The Adolescent Physical Activity Questionnaire, developed by Kowalski and colleagues in 1997 to assess the physical activity levels of high school students, is an 8-item, 5-point Likert scale tool based on recalling the past 7 days. The 8 items in the scale are used to calculate the physical activity score. The 9th item inquires whether the participant was ill during the past week or if there was any condition preventing normal physical activity. However, this item is not included in the scoring. The first item lists 24 types of physical activity. The frequency of each activity is scored as "never" (1 point), "1-2" (2 points), "3-4" (3 points), "5-6" (4 points), or "7 or more times" (5 points). The result is divided by 24 to obtain the activity score for this item. For items 2-7, responses start with the lowest level of physical activity (1 point) and increase to the highest level (5 points). Item 8 evaluates the frequency of physical activity over the 7 days of the week. Responses a

    Time frame: Baseline

Secondary outcomes

  1. Physical Activity Participation Motivation Scale

    This scale was developed to assess the motivation of high school students to participate in physical activity. It is a 16-item scale consisting of three factors: individual reasons, environmental reasons, and lack of reasons. In the study, the scale items are rated using a 5-point Likert scale: "Strongly disagree," "Disagree," "Undecided," "Agree," and "Strongly agree." The lowest possible score on the scale is 16, and the highest score is 80. Higher scores indicate more positive motivation to participate in physical activity. In this context, the scores on the Physical Activity Participation Motivation Scale are interpreted as follows: 1-16 indicates very low motivation, 17-32 indicates low motivation, 33-48 indicates medium motivation, 49-64 indicates high motivation, and 65-80 indicates very high motivation for physical activity participation. Items 3, 9, 13, 14, 15, and 16 are reverse-scored. The Cronbach alpha values range from 0.82 to 0.89, indicating good reliability.

    Time frame: Baseline

  2. Physical Activity Competence Scale

    Physical Activity Competence Scale (PACS), adolescents' physical activity competence in different physical activity areas (at school, in transportation, at home, leisure and recreation, and school-based walking and transportation) is a 5-dimensional and 26-item scale developed to assess their competence. PACS consists of 5 dimensions and 26 items (At school: 6 items, In transportation: 3 items, At home: 5 items, Leisure and recreation: 6 items, School-based walking and transportation: 6 items). The scale form consists of two parts. The first part contains demographic information, and in the second part, participants are asked how confident they are in participating in physical activities in the five physical activity areas. A 10-point Likert-type scale (0 = "I have no confidence" and 100 = "I have full confidence") is used for the items. The total average score is calculated from the answers to the items in each domain and ranges between 0 and 100.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Aug 2025, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartEst.
May 15, 2025
Primary completionEst.
Aug 15, 2025
CompletionEst.
Nov 15, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974942
Responsible party
Nilay Arman (PhD, Istanbul University - Cerrahpasa) — Principal investigator
First posted
May 16, 2025
Start date
May 15, 2025 (estimated)
Primary completion
Aug 15, 2025 (estimated)
Completion
Nov 15, 2025 (estimated)
Last update
May 16, 2025

Study contacts

Nilay Arman, PhD
Contact
nilayarman@iuc.edu.tr
0553 455 87 07
Asya Albayrak, MSc
Contact
0538 396 89 50

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion